JP7561134B2 - 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 - Google Patents

合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 Download PDF

Info

Publication number
JP7561134B2
JP7561134B2 JP2021553767A JP2021553767A JP7561134B2 JP 7561134 B2 JP7561134 B2 JP 7561134B2 JP 2021553767 A JP2021553767 A JP 2021553767A JP 2021553767 A JP2021553767 A JP 2021553767A JP 7561134 B2 JP7561134 B2 JP 7561134B2
Authority
JP
Japan
Prior art keywords
cancer
replicon rna
oncolytic virus
virus
synthetic oncolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524391A5 (enExample
JP2022524391A (ja
Inventor
アーバイン，ダレル，ジェイ．
ウィトラップ，カール，デーン
ワイス，ロン
リー，インジョン
ムミン，ノア
ドン，イージョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2022524391A publication Critical patent/JP2022524391A/ja
Publication of JP2022524391A5 publication Critical patent/JP2022524391A5/ja
Priority to JP2024163492A priority Critical patent/JP2025011109A/ja
Application granted granted Critical
Publication of JP7561134B2 publication Critical patent/JP7561134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021553767A 2019-03-08 2020-01-10 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 Active JP7561134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163492A JP2025011109A (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163492A Division JP2025011109A (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Publications (3)

Publication Number Publication Date
JP2022524391A JP2022524391A (ja) 2022-05-02
JP2022524391A5 JP2022524391A5 (enExample) 2023-01-23
JP7561134B2 true JP7561134B2 (ja) 2024-10-03

Family

ID=69526302

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553767A Active JP7561134B2 (ja) 2019-03-08 2020-01-10 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用
JP2024163492A Pending JP2025011109A (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163492A Pending JP2025011109A (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Country Status (19)

Country Link
US (3) US11717548B2 (enExample)
EP (2) EP3934673B1 (enExample)
JP (2) JP7561134B2 (enExample)
KR (2) KR20250171410A (enExample)
CN (1) CN113966221B (enExample)
AU (1) AU2020233788A1 (enExample)
BR (1) BR112021017637A8 (enExample)
CA (1) CA3132714A1 (enExample)
CO (1) CO2021013417A2 (enExample)
DK (1) DK3934673T3 (enExample)
ES (1) ES3066636T3 (enExample)
FI (1) FI3934673T3 (enExample)
IL (1) IL285963A (enExample)
MX (1) MX2021010808A (enExample)
MY (1) MY207334A (enExample)
PH (1) PH12021552145A1 (enExample)
PT (1) PT3934673T (enExample)
SG (1) SG11202109514VA (enExample)
WO (1) WO2020185293A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025011109A (ja) * 2019-03-08 2025-01-23 マサチューセッツ インスティテュート オブ テクノロジー 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
IL316186A (en) 2022-04-26 2024-12-01 Strand Therapeutics Inc Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
JP2026502453A (ja) * 2023-01-12 2026-01-23 バヴァリアン・ノルディック・アクティーゼルスカブ がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ）
WO2024211865A2 (en) * 2023-04-07 2024-10-10 Omega Therapeutics, Inc. Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
KR20260046366A (ko) 2023-07-25 2026-04-07 스트랜드 세러퓨틱스 인코포레이티드 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도
WO2025087372A1 (zh) * 2023-10-27 2025-05-01 上海元宋生物技术有限公司 溶瘤病毒及其用途
CN119479778B (zh) * 2024-10-16 2025-04-25 北京悦康科创医药科技股份有限公司 一种lnp转染效率预测模型构建方法及装置
CN121081290B (zh) * 2025-11-12 2026-03-10 佑嘉(杭州)生物医药科技有限公司 一种毛囊靶向递送系统及生发防脱化妆品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180147166A1 (en) 2015-05-21 2018-05-31 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US11291635B2 (en) * 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2014089061A1 (en) * 2012-12-03 2014-06-12 Yasuko Rikihisa Ehrlichial invasin for immunization, diagnosis, and cell delivery
CN107072946B (zh) * 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
RU2739794C2 (ru) * 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
KR20250171410A (ko) * 2019-03-08 2025-12-08 메사추세츠 인스티튜트 오브 테크놀로지 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
CN116710079A (zh) * 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
US20240140960A1 (en) * 2021-02-12 2024-05-02 Ohio State Innovation Foundation Sugar derived lipid nanomaterials and uses thereof
CN117897494A (zh) * 2021-07-09 2024-04-16 瑞普利科特生物科学公司 经修饰的东方马脑炎病毒、自复制rna构建体及其用途
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180147166A1 (en) 2015-05-21 2018-05-31 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cellular and Molecular Bioengineering，2018年，11(5)，pp.397-406
Nano Letters，2017年，17(3），pp.1326-1335
Vaccines，2016年，4(4):39，pp.1-23

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025011109A (ja) * 2019-03-08 2025-01-23 マサチューセッツ インスティテュート オブ テクノロジー 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Also Published As

Publication number Publication date
BR112021017637A8 (pt) 2022-08-16
KR20250171410A (ko) 2025-12-08
WO2020185293A1 (en) 2020-09-17
KR102889984B1 (ko) 2025-11-25
CN113966221B (zh) 2026-03-31
DK3934673T3 (da) 2026-04-07
US20200281994A1 (en) 2020-09-10
PH12021552145A1 (en) 2022-08-31
ES3066636T3 (en) 2026-05-13
BR112021017637A2 (enExample) 2021-11-09
SG11202109514VA (en) 2021-09-29
CN113966221A (zh) 2022-01-21
FI3934673T3 (fi) 2026-03-31
CA3132714A1 (en) 2020-09-17
MX2021010808A (es) 2021-12-15
MY207334A (en) 2025-02-19
KR20220006041A (ko) 2022-01-14
US20240024394A1 (en) 2024-01-25
US20260061013A1 (en) 2026-03-05
CO2021013417A2 (es) 2022-01-17
AU2020233788A1 (en) 2021-10-07
PT3934673T (pt) 2026-04-07
EP3934673A1 (en) 2022-01-12
US12383589B2 (en) 2025-08-12
JP2022524391A (ja) 2022-05-02
IL285963A (en) 2021-10-31
EP4729621A2 (en) 2026-04-22
US11717548B2 (en) 2023-08-08
EP3934673B1 (en) 2026-01-07
JP2025011109A (ja) 2025-01-23

Similar Documents

Publication Publication Date Title
US12383589B2 (en) Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy
Pardi et al. mRNA vaccines—a new era in vaccinology
ES2279580T3 (es) Composiciones para administrar genes a celulas de la piel que presentan antigenos.
US20170218369A1 (en) An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
US20230295257A1 (en) Lipid nanoparticle comprising modified nucleotides
TW202600150A (zh) 編碼ccl21之重組棒狀病毒
Loomis et al. Strategies for modulating innate immune activation and protein production of in vitro transcribed mRNAs
CN119563028A (zh) 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
Huang et al. Advances in development of mRNA-based therapeutics
US20210205475A1 (en) Mitochondrial optogenetics-based gene therapy for treating cancer
US20240166707A1 (en) Expression constructs and uses thereof
JP2017523783A (ja) アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用
US20220403416A1 (en) Polymer-Encapsulated Viral Vectors for In Vivo Genetic Therapy
EP4514328A1 (en) Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
KR20260046366A (ko) 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도
CN118662522B (zh) Mir2911在制备抗黄热病毒yfv的药物中的应用
RU2809724C2 (ru) Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей
US20240366740A1 (en) Interleukin-12 self-replicating rna and methods
TW202604543A (zh) 於實體腫瘤的ｐ２１工程化單核球及放射療法
Brown Development of Genetic Medicines for the Treatment and Prevention of Infectious Disease, Cancer, and Aging
EA052099B1 (ru) Экспрессионные конструкции и их применения для лечения рака
Mishra et al. Next-Generation Therapy: mRNA Redefining Pharmacy Practice
WO2025257084A1 (en) Lipid composition
CN116334038A (zh) 一种dna表达增强因子及其应用
JP2026513742A (ja) 合成回路及びその使用

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240920

R150 Certificate of patent or registration of utility model

Ref document number: 7561134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150